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Abstract
Background: Leading malaria vaccine, RTS,S, is based on the circumsporozoite protein (CSP) of sporozoites. RTS,S
confers partial protection against malaria in children, but efficacy wanes relatively quickly after primary
immunization. Vaccine efficacy has some association with anti-CSP IgG; however, it is unclear how these antibodies
function, and how functional antibodies are induced and maintained over time. Recent studies identified antibody-
complement interactions as a potentially important immune mechanism against sporozoites. Here, we investigated
whether RTS,S vaccine-induced antibodies could function by interacting with complement.
Methods: Serum samples were selected from children in a phase IIb trial of RTS,S/AS02A conducted at two study
sites of high and low malaria transmission intensity in Manhiça, Mozambique. Samples following primary
immunization and 5-year post-immunization follow-up time points were included. Vaccine-induced antibodies were
characterized by isotype, subclass, and epitope specificity, and tested for the ability to fix and activate complement.
We additionally developed statistical methods to model the decay and determinants of functional antibodies after
vaccination.
Results: RTS,S vaccination induced anti-CSP antibodies that were mostly IgG1, with some IgG3, IgG2, and IgM.
Complement-fixing antibodies were effectively induced by vaccination, and targeted the central repeat and C-
terminal regions of CSP. Higher levels of complement-fixing antibodies were associated with IgG that equally
recognized both the central repeat and C-terminal regions of CSP. Older age and higher malaria exposure were
significantly associated with a poorer induction of functional antibodies. There was a marked decay in functional
complement-fixing antibodies within months after vaccination, as well as decays in IgG subclasses and IgM.
Statistical modeling suggested the decay in complement-fixing antibodies was mostly attributed to the waning of
anti-CSP IgG1, and to a lesser extent IgG3.
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Conclusions: We demonstrate for the first time that RTS,S can induce complement-fixing antibodies in young
malaria-exposed children. The short-lived nature of functional responses mirrors the declining vaccine efficacy of
RTS,S over time. The negative influence of age and malaria exposure on functional antibodies has implications for
understanding vaccine efficacy in different settings. These findings provide insights into the mechanisms and
longevity of vaccine-induced immunity that will help inform the future development of highly efficacious and long-
lasting malaria vaccines.
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Background
There is an unmet need for highly efficacious malaria
vaccines, which would substantially reduce worldwide
morbidity and mortality and accelerate malaria elimin-
ation. To date, only one candidate has been tested in
phase III clinical trials, the RTS,S subunit vaccine ad-
ministered with AS01B adjuvant (liposome-based adju-
vant). Thousands of children and infants were enrolled
from multiple study sites across sub-Saharan Africa, and
RTS,S was moderately efficacious against clinical malaria
at 38–48months follow-up (36.3% and 25.9% after the
fourth booster at 20 months in children and infants, re-
spectively) [1]. RTS,S has received a positive scientific
opinion by the European Medicines Agency [2] and will
undergo pilot implementation in areas of Ghana, Kenya,
and Malawi to further evaluate vaccine safety, reduction
in childhood mortality, and feasibility of the four-dose
vaccine regimen [3, 4]. Despite this achievement, vaccine
efficacy against clinical malaria was well below the target
of 75% as set by the World Health Organization [5], and
longitudinal studies show that protection rapidly de-
clines after vaccination [1].
RTS,S is based on the major surface expressed antigen
on Plasmodium falciparum sporozoites, the circumspor-
ozoite protein (CSP). The vaccine construct is a fusion
protein between a truncated form of CSP (containing
the central repeat and C-terminal regions only) and
hepatitis B surface antigen that is co-expressed with un-
fused hepatitis B surface antigen, which self-assemble as
virus-like particles. The central repeat region is a tan-
dem repeat of amino acid sequence NANP that is a
known B cell epitope, and the C-terminal region con-
tains B and T cell epitopes [6]. High levels of immuno-
globulin G (IgG) to the central repeat region have been
broadly associated with protection against clinical mal-
aria in RTS,S vaccine trials [7]. A recent study was the
first to report the specific IgG subclass responses in-
duced by RTS,S/AS01B in infants and young children
(age groups, 6–12 weeks and 5–17months) and identi-
fied that IgG3 to the central repeat region and IgG1 and
IgG3 to the C-terminal region were associated with pro-
tection [8]. However, the mechanisms of such antibodies
and how they confer protection are undefined. Further
research is needed to understand the mechanisms of
RTS,S-induced immunity and why efficacy is short-lived
so that strategies to enhance vaccine efficacy and longev-
ity in target populations can be developed.
Healthy malaria-naïve adults vaccinated with RTS,S
develop antibodies that can block sporozoite infectivity
and mediate opsonic phagocytosis using the THP-1
monocyte cell line in vitro. How this relates to protec-
tion is somewhat unclear, particularly for the latter
mechanism, which has had conflicting findings [9–11].
Complement fixation and activation by antibodies is an
important mechanism of humoral immunity to some
viral and bacterial pathogens [12–14] and has been pro-
posed to play a role in immunity against blood-stage P.
falciparum infection [15]. We have recently demon-
strated that naturally acquired human antibodies, or
antibodies generated by repeated experimental inocula-
tion of healthy volunteers with sporozoites, can promote
fixation of complement factor C1q and activate the clas-
sical complement pathway against P. falciparum sporo-
zoites [16, 17]. This antibody-complement interaction
inhibited the traversal mode of sporozoite motility and
led to cell death. Antibodies targeting CSP could also
promote complement fixation [17]. Additionally, high
levels of naturally acquired complement-fixing anti-
bodies were associated with a reduced risk of clinical
malaria in a longitudinal study of children [17]. This in-
dicated that antibody-complement activity is an import-
ant mechanism of human immunity against sporozoites
and raised the question of whether it may also be a func-
tional mechanism induced by RTS,S.
Here, we examined antibody responses from a phase
IIb clinical trial of RTS,S administered with AS02A adju-
vant (formerly used adjuvant that is an oil-in-water
emulsion) in children resident in Manhiça, Mozambique,
that was conducted at two study sites of different mal-
aria transmission intensity [18]. We aimed to
characterize RTS,S-induced antibodies by isotype, IgG
subclass, and reactivity to different CSP regions, and to
determine whether antibodies induced by RTS,S func-
tion by fixing complement. Furthermore, we aimed to
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understand the influence of antibody types and levels of
malaria exposure on complement-fixing activity. We
then developed statistical models of the decay of
complement-fixing antibodies, IgG subclass responses,
and IgM over 5 years of follow-up and explored which




Serum samples were obtained from a previously con-
ducted randomized control phase IIb clinical trial of the
RTS,S/AS02A vaccine (ClinicalTrials.gov registry number
NCT00197041). The study was conducted in
Mozambique at two study sites to evaluate protective ef-
ficacy against clinical disease (Manhiça, cohort 1) and
new infection (Ilha Josina, cohort 2). Notably, malaria
transmission intensity was low to moderate at the Man-
hiça study site and high at the Ilha Josina study site.
Children aged 1 to 4 years were enrolled and adminis-
tered three doses of RTS,S/AS02A at months 0, 1, and 2
of the study or comparator vaccines as previously de-
scribed [18]. We tested sera from a random selection of
participants collected at baseline (month 0, M0) and 30
days after receiving the third and final RTS,S vaccination
(month 3, M3) from Manhiça (RTS,S N = 50, comparator
N = 25) and Ilha Josina (RTS,S N = 49, comparator N =
24) cohorts. We additionally tested sera from the Man-
hiça cohort collected during a 5-year follow-up to assess
long-lived immune responses (months 8.5, 21, 33, 45,
and 63, n = 30). Sample selection was at random and
summary statistics closely matched that of the entire co-
hort (median age, 2.8 years and 2.5 years; male-to-female
ratio, 0.93 and 0.83; Manhiça malaria
negative-to-positive ratio, 0.17 and 0.15; Ilha Josina mal-
aria negative-to-positive ratio, 2.32 and 1.41, respect-
ively). Individuals tested at later time points were
randomly selected from those with sufficient volumes at
all time points (out of n = 371). Note that all serum sam-
ples were heat treated for 45 min at 56 °C to inactivate
any host complement proteins.
Experimenter blinding
Experimenters were blinded from the vaccine group, age
group, and study site until all participants had been
tested for IgG, immunoglobulin M (IgM), and
C1q-fixation to CSP.
Antigens
The following antigens used in this study were all based
on P. falciparum 3D7: recombinant CSP beginning at
amino acid residue 50 that contained (NANP)22 repeats
and (NVPD)4 repeats expressed in Pichia pastoris
(Sanaria, Rockville, USA), synthetic (NANP)15 peptide
(NANP) representing the central repeat region of CSP
(Life Tein, Hillsborough, USA), recombinant C-terminal
region (CT) of CSP expressed in HEK293 cells at Burnet
Institute (as described in Additional file 1: Figure S1), re-
combinant merozoite surface protein 2 (MSP2), and ap-
ical membrane antigen 1 (AMA1) both expressed in
Escherichia coli as previously described [19, 20].
Antibody detection assay
Sera were tested by standard enzyme-linked immuno-
sorbent assay (ELISA) to detect antibody reactivity as
follows. Ninety-six-well flat bottom MaxiSorp plates
(Thermo Fisher Scientific, Waltham, USA) were coated
in 0.5 μg/ml antigen in phosphate-buffered saline (PBS)
overnight at 4 °C. Plates were washed (thrice with
PBS-Tween20 0.05%) using the ELx405 automated plate
washer (BioTeck, Winooski, USA) and blocked with 1%
casein in PBS (w/v) for 2 h at 37 °C. Plates were washed
and then incubated with human sera (tested in dupli-
cate) in buffer (0.1% casein in PBS, v/v) for 2 h at room
temperature (RT). Sera were tested at 1/4000 dilution
for IgG and IgG subclass detection and 1/500 for IgM
detection (note that for the decay analysis, samples col-
lected between M3 and M63 were tested at 1/500 for
IgG subclass detection). Plates were washed, and anti-
body isotypes were detected using goat anti-human IgG
and IgM conjugated to horseradish peroxidase (HRP,
Millipore, Burlington, USA) at 1/2500 dilution in buffer
for 1 h at RT. Plates were washed for a final time and in-
cubated with 2,2′-azino-bis(3-ethylbenzothiazoline-6--
sulfonic acid) substrate (ABTS, Thermo Fisher
Scientific) shielded from light at RT. IgG and IgM reac-
tivities were measured after 20 and 60 min, respectively,
at an optical density (OD) of 405 nm using the Multis-
kan Go plate reader (Thermo Fisher Scientific).
To detect IgG subclasses, plates were instead incu-
bated with mouse anti-human IgG1, IgG2, IgG3, and
IgG4 (Thermo Fisher Scientific), washed, and then incu-
bated with goat anti-mouse IgG HRP (Millipore) all at
1/1000 dilution in buffer for 1 h at RT. Plates were
washed for a final time and incubated with tetramethyl-
benzidine substrate (TMB, Thermo Fisher Scientific)
shielded from light at RT. IgG subclass reactivity was
stopped after 30 min of incubation using 1M sulfuric
acid, and OD was measured at 450 nm. We have previ-
ously confirmed the specificity and sensitivity of the IgG
subclass reagents used [21]. A prior report of IgG sub-
class responses induced by RTS,S in the phase III trial
[8] used a suspension bead array method rather than
ELISA. While there may be differences between these
methods, prior evaluation of the two approaches for de-
tection of malaria antibodies using a range of antigens
suggested the two methods were comparable [22].
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Complement fixation assay
Sera were tested for the ability to fix complement
using the plate-based complement fixation assay as
previously described [17]. Briefly, coating and block-
ing were conducted as described above for antibody
detection. Plates were incubated with human sera
(tested in duplicate) at 1/250 dilution in buffer for 2 h
at RT (note that for the decay analysis, samples col-
lected M3-M63 were re-tested at 1/110 dilution for
C1q-fixation). Plates were washed and incubated with
purified human C1q (Millipore) at 10 μg/ml in buffer
for 30 min, followed by washing. To detect
C1q-fixation, plates were incubated with rabbit
anti-C1q IgG (in-house), washed, and then incubated
with goat anti-rabbit IgG HRP (Millipore) both at 1/
2000 dilution in buffer for 1 h at RT. Detection anti-
bodies were validated as described in Additional file 1:
Figure S2. Plates were washed for a final time and in-
cubated with TMB shielded from light at RT.
C1q-fixation reactivity was stopped after 30 min of in-
cubation using 1M sulfuric acid, and OD was mea-
sured at 450 nm.
We additionally tested a random selection of n = 20 in-
dividuals (from the RTS,S vaccine group collected at 3
M) for C5b-C9-fixation to CSP. This was conducted
using the same protocol, but fresh human serum pooled
from malaria-naïve donors was used as a source of com-
plement (1/10 dilution), and rabbit anti-C5b-C9 detec-
tion antibodies were used (1/1000 dilution).
Experimental controls and standardization
To ensure accurate results, human serum samples were
tested in duplicate, and those with high variability (> 25%)
were re-tested or excluded (unless duplicates differed OD
< 0.1). Raw data were corrected for background reactivity
using no-serum/blank negative controls and adjusted for
plate-to-plate variation using malaria-exposed positive
controls that were included on each plate. We also in-
cluded malaria-naïve negative controls from Melbourne
donors (N = 24), and test samples with an OD greater than
the mean + 3 standard deviations of the Melbourne con-
trols were considered positive.
We also examined the epitope specificity of individuals
and considered the ratio of NANP-to-CT IgG as equal if
the variability between NANP and CT responses was <
25%, which was the acceptable range for duplicate variabil-
ity. Individuals who exceeded this were considered as hav-
ing a NANP (ratio > 1.25) or CT-skewed (ratio < 0.75) IgG
response.
Statistical analysis
For descriptive and comparative analysis, the median
and interquartile range (IQR) were reported, and the fol-
lowing two-tailed non-parametric tests were performed
where appropriate (GraphPad Prism 7; p < 0.05 was con-
sidered significant): Mann-Whitney U test, Wilcoxon
matched-pairs signed-rank test, and Spearman’s correl-
ation coefficient (Rho).
Statistical models were developed to investigate (i)
decay rates of complement-fixing antibodies, anti-
body isotypes, and IgG subclasses and (ii) the rela-
tionship between complement-fixing antibodies and
different antibody types using repeated measures
longitudinal data (Stata version 14, StataCorp). Given
the dependency on the data from repeated measure-
ment, multilevel modelling was used to estimate la-
tent growth curve models exploring the
subject-specific nature of the association between
time and C1q-fixation, IgG subclasses, and IgM.
Given the non-linear functional form of the associ-
ation between time and C1q-fixation, IgG subclasses,
and IgM, latent growth curve models regressed the
log of C1q-fixation and IgG subclass and IgM on log
time, and post-estimation non-linear equations using
exponentiated model coefficients were used to pro-
vide proportional rates of change at specific time
points. Latent growth curve models comprised two
levels, individuals at level 2 (i.e., random intercept
and coefficient for time) and their C1q-fixation, IgG
subclass, and IgM response across time at level 1
(see Additional file 1: Supplementary equation 1).
Nested model-based likelihood ratio statistics were
used to provide statistical inference for model fit
when relaxing model constraints (random effects and
the functional form of fixed effects for time) and
Akaike Information Criterion (AIC) and Bayesian In-
formation Criterion (BIC) fit statistics used to in-
form functional form modeling across non-nested
models. To further assess the fit of the estimated la-
tent growth curve models, diagnostic plots compar-
ing participants observed marker levels with
Bayesian model-based (best linear unbiased predic-
tions) predicted levels over time were produced and
examined.
Contemporaneous (i.e., both outcome and factor vari-
able responses from the same time period were
regressed) unadjusted and adjusted longitudinal associa-
tions between C1q-fixation, IgG subclass, and IgM levels
were also estimated using multilevel modelling. Level-1
error variance estimates from nested regression model-
ing based on these analyses were used to derive Cohen’s
f2 measures of effect for each IgG subclass and IgM [23].
In these multilevel models, IgG subclass and IgM were
estimated as log time-varying fixed factors and their
effects unconstrained by time. In addition to these
terms, both fixed and random terms for log time were
also estimated and a random effect (intercept (level 2))
to account for the dependency C1q-fixation level
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measurement over-time was also estimated. Statistical
inference was assessed at the 5% level.
Results
RTS,S-induced anti-CSP IgG in children is predominately
IgG1 subclass
Sera collected at baseline (M0) and 30 days after receiv-
ing the final RTS,S vaccination (M3) were tested for total
IgG levels to full-length CSP. Reactivity was low at base-
line but significantly increased after vaccination with
RTS,S in both study cohorts (OD median [IQR]: Man-
hiça N = 50, M0 = 0.020 [0.022], and M3 = 2.231 [0.390],
p < 0.001; Ilha Josina N = 49, M0 = 0.030 [0.039], and
M3 = 2.457 [0.425], p < 0.001). In contrast, anti-CSP IgG
was low at both time points in children who received
the comparator non-malaria vaccine (OD median [IQR]:
Manhiça N = 25, M0 = 0.015 [0.020], and M3 = 0.018
[0.054], p = 0.525; Ilha Josina N = 24, M0 = 0.029 [0.037],
and M3 = 0.038 [0.045], p = 0.747) (Fig. 1a).
Children vaccinated with RTS,S (sera collected at M3)
were then tested for IgG subclass responses to CSP.
Seropositivity was high for IgG1 (94% and 98%) and
IgG3 (90% and 96%), followed by IgG2 (70% and 86%)
and IgG4 (22% and 51%) in Manhiça and Ilha Josina co-
horts, respectively (Fig. 1b). Overall, IgG1 reactivity was
highest, followed by IgG3 and IgG2, and only low levels
of IgG4 were detected among a minority of subjects.
IgG1 demonstrated the strongest correlation with total
IgG compared to IgG3 and IgG2, with only a weak cor-
relation for IgG4 (rho = 0.875, rho = 0.689, rho = 615,
p < 0.001 for all tests; rho = 0.208, p = 0.039, respectively)
(Additional file 1: Figure S3a).
RTS,S vaccination induced anti-CSP IgM
We additionally measured IgM levels to CSP at M0 and
M3 time points since the induction of IgM may contrib-
ute to complement-fixing activity and overall vaccine
immunity. To date, there are little data reported on the
induction of IgM by RTS,S/AS02A. There was a signifi-
cant increase in IgM reactivity for children vaccinated
with RTS,S in both cohorts (OD median [IQR]: Manhiça
N = 50, M0 = 0.208 [0.178], and M3 = 0.725 [0.912],
p < 0.001; Ilha Josina N = 49, M0 = 0.191 [0.227], and
M3 = 0.736 [0.726], p < 0.001) but not with comparator
vaccine (OD median [IQR]: Manhiça N = 25, M0 = 0.194
[0.198], and M3 = 0.194 [0.151], p = 0.300; Ilha Josina N
= 24, M0 = 0.225 [0.200], and M3 = 0.142 [0.157],
p = 0.089) (Fig. 1c). Furthermore, anti-CSP IgM levels at
M3 were significantly higher in the RTS,S vaccine group
than the comparator vaccine group for both study sites
(p < 0.001 for both tests). In all RTS,S-vaccinated chil-
dren (N = 99), anti-CSP IgG and IgM responses at M3
moderately correlated, but many demonstrated IgG-
high/IgM-low reactivity. Notably, IgM reactivity at M0
and M3 was weakly correlated (rho = 0.254; p = 0.011)
(Additional file 1: Figure S3b).
RTS,S-induced antibodies can fix and activate
complement
We have previously reported that anti-CSP antibodies
can activate human complement through recruitment of
C1q [17]. In this study, we detected a strong induction
of functional antibodies that fix C1q in children
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Fig. 1 RTS,S vaccine-induced IgG and IgM antibodies to CSP.
Children in RTS,S and comparator vaccine groups from Manhiça
(black box plots; N = 50 and N = 25, respectively) and Ilha Josina
cohorts (gray box plots; N = 49 and N = 24, respectively) were tested
for IgG (a), IgG subclasses (b), and IgM (c) to CSP. Sera collected at
baseline (month 0, M0) and after vaccination (month 3, M3) were
tested in duplicate (note that only M3 was tested in b), and the
mean value was used to generate box plots whereby top, center,
and bottom horizontal lines represent the 75th percentile, median,
and 25th percentile, respectively; upper and lower whiskers
represent the highest and lowest values within 1.5× IQR,
respectively; and values that exceed this range are presented as
dots. Malaria-naïve negative controls from Melbourne donors were
used to calculate the seropositivity cutoff value (dashed lines), and
the percentage of individuals above this threshold are shown.
Reactivity between paired samples and unpaired samples were
compared using Wilcoxon matched-pairs signed-rank test and
Mann-Whitney U test, respectively
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vaccinated with RTS,S, which was observed in both
study sites (OD median [IQR]: Manhiça N = 50,
M0 = 0.029 [0.054], and M3 = 1.913 [3.163], p < 0.001;
Ilha Josina N = 49, M0 = 0.013 [0.038], and M3 = 2.508
[2.701], p < 0.001). However, this induction of
complement-fixing antibodies was not seen with the
comparator vaccine (Fig. 2a). RTS,S-induced antibodies
could promote activation of the complement cascade, as
demonstrated by the presence of complement factors in-
volved in the terminal phase of complement activation
that form the membrane attack complex (C5b-C9).
Detection of the C5b-C9 complex significantly corre-
lated with C1q-fixation (n = 20, rho = 0.937; p < 0.001)
(Fig. 2b).
Complement-fixing antibodies target the central repeat
and C-terminal regions of CSP
To investigate the targets of functional antibodies in-
duced by RTS,S, we first measured antibody reactivity to
NANP and CT antigens, which represented the central
repeat and C-terminal regions of CSP, respectively
(Fig. 3a, b). Compared to baseline, children vaccinated
with RTS,S had significantly higher levels of IgG to both
regions of CSP (p < 0.001 for all tests), whereas IgM was
mostly NANP-specific (NANP, p < 0.001 for all tests; CT,
p = 0.032 and p = 0.177 for Manhiça and Ilha Josina co-
horts, respectively).
Interestingly, IgG reactivity to NANP and CT signifi-
cantly correlated with C1q-fixation to full-length CSP,
suggesting both regions were involved in the functional
activity (rho: NANP = 0.727 and CT = 0.676; p < 0.001
for both tests) (Fig. 3c). Indeed, we confirmed that
antibodies to each region of CSP could directly fix C1q
using specific antigen constructs, although complement-
fixing activity was greater against NANP than CT, and
correlated more strongly with C1q-fixation to full-length
CSP (OD median [IQR]: NANP = 1.25 [2.34] and
CT = 0.14 [0.24]; rho: NANP = 0.926 and CT = 0.730;
p < 0.001 for both tests) (Fig. 3d).
We then compared antibody responses between chil-
dren who had high or low levels of complement-fixing
antibodies to CSP (defined based on the median: high N
= 50, OD range 2.03 to 4.00; low N = 49, OD range 0.02
to 1.97). Notably, children with high C1q-fixing anti-
bodies had substantially higher levels of IgG to both
NANP and CT and higher levels of IgM to NANP (IgG:
NANP p < 0.001, CT p < 0.001; IgM: NANP p < 0.001,
CT p = 0.038) (Additional file 1: Figure S4). We further
examined the epitope specificity using heat maps and
found high variability among individuals with respect to
IgG and IgM levels to the different regions (Fig. 4a). We
explored different approaches to identify potential influ-
encing factors for complement fixation activity. Linear
regression for anti-NANP IgG with the additional
inclusion of anti-CT IgG did not substantially improve
the fit of the model overall compared to IgG to NANP
alone, and we found no significant linear relationship
between epitope-specific IgM by linear regression
(Additional file 1: Table S1). Given the observed variabil-
ity in IgG responses to the NANP and CT regions, we
calculated the ratio of NANP-to-CT IgG, which was
used to categorize children in equal, NANP-skewed, or
CT-skewed IgG epitope profiles (defined by ratios of
0.75 to < 1.25, > 1.25, and < 0.75, respectively) (Fig. 4b).
Interestingly among the high complement-fixing group,
a greater proportion had relatively equal levels of IgG to
both NANP and CT (63%), while some were
NANP-skewed (27%) and fewer CT-skewed (10%). For
children with low C1q-fixing antibodies, all three epitope
profiles were equally observed (33% each) (Fig. 4c). This
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Fig. 2 RTS,S vaccine-induced antibodies promote complement fixation to CSP. a Children in RTS,S and comparator vaccine groups from Manhiça
(black box plots; N = 50 and N = 25, respectively) and Ilha Josina cohorts (gray box plots; N = 49 and N = 24, respectively) were tested for C1q-
fixation to CSP. Sera collected at baseline (month 0, M0) and after vaccination (month 3, M3) were tested in duplicate, and the mean value was
used to generate box plots whereby top, center, and bottom horizontal lines represent the 75th percentile, median, and 25th percentile,
respectively; upper and lower whiskers represent the highest and lowest values within 1.5× IQR, respectively; and values that exceed this range
are presented as dots. Malaria-naïve negative controls from Melbourne donors were used to calculate the seropositivity cutoff values (dashed
lines), and the percentages of individuals above this threshold are shown. Reactivity between paired samples and unpaired samples were
compared using Wilcoxon matched-pairs signed-rank test and Mann-Whitney U test, respectively. b Random selection of children in the RTS,S
vaccine group from Manhiça cohort (n = 20, M3) were tested for C5b-C9-fixation to CSP, and the mean of duplicates was graphed as scatter plots
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suggests that IgG reactivity to both regions may be fa-
vorable for C1q-fixation to full-length CSP.
Poor induction of functional antibodies in children with
higher malaria exposure and blood-stage immunity
To evaluate the potential effect of malaria exposure on
the induction of complement-fixing antibodies, we com-
pared RTS,S-induced functional antibodies (sera col-
lected at M3) in younger and older age groups (12–24
and 24–60months, respectively) and between our two
different study sites (Additional file 1: Figure S5a). Chil-
dren in the Manhiça cohort demonstrated no relation-
ship between age and C1q-fixation to CSP (younger
n = 11 and older n = 39, p = 0.579; rho = − 0.121,
p = 0.403). For the Ilha Josina cohort, which had a sub-
stantially higher level of malaria transmission than Man-
hiça, younger children had significantly higher levels of
C1q-fixing antibodies (younger n = 23 and older n = 26,
p < 0.001), and age negatively correlated with C1q-
fixation (rho = − 0.575, p < 0.001). Similar age associa-
tions were also observed for C1q-fixation to NANP
(Fig. 5a) as well as anti-CSP IgG and IgG subclass
responses. However, anti-CSP IgM was comparable be-
tween the age groups for the Ilha Josina cohort but was
interestingly higher in older children for the Manhiça
cohort (Additional file 1: Figures S5b-d).
The Ilha Josina study site had a higher level of malaria
transmission intensity than Manhiça, indicating that age
associations may be related to malaria exposure. To in-
vestigate, we measured antibody responses to well-
characterized blood-stage antigens, MSP2 and AMA1,
which are established biomarkers of malaria exposure
[24] (Fig. 5b). The relationship between age and
blood-stage antibodies was weak for the Manhiça cohort
(MSP2 p = 0.112 and AMA1 p = 0.009; correlation with
age, MSP2 rho = 255, p = 0.074, and AMA1 rho = 0.302,


































































































Fig. 3 Functional complement-fixing antibodies target the central repeat and C-terminal regions of CSP. Children in RTS,S vaccine group from
Manhiça (black box plots; N = 50) and Ilha Josina cohorts (gray box plots; N = 49) were tested for IgG (a) and IgM (b) to NANP and CT regions of
CSP. Sera collected at baseline (month 0, M0) and after vaccination (month 3, M3) were tested in duplicate, and the mean value was used to
generate box plots whereby top, center, and bottom horizontal lines represent the 75th percentile, median, and 25th percentile, respectively;
upper and lower whiskers represent the highest and lowest values within 1.5× IQR, respectively; and values that exceed this range are presented
as dots. Malaria-naïve negative controls from Melbourne donors were used to calculate the seropositivity cutoff values (dashed lines), and the
percentages of individuals above this threshold are shown. Reactivity between paired samples was compared using Wilcoxon matched-pairs
signed-rank test. c, d Children in RTS,S vaccine group from Manhiça and Ilha Josina cohorts (N = 99, M3) were tested for C1q-fixation to CSP,
NANP, and CT, and the values were plotted compared to IgG reactivity (c) and C1q fixation to CSP, NANP, and CT were correlated (d)
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p = 0.033) but strong for the Ilha Josina cohort (MSP2
p < 0.001 and AMA1 p < 0.001; correlation with age,
MSP2 rho = 0.595, p < 0.001, and AMA1 rho = 0.605,
p < 0.001). Furthermore, in the Ilha Josina cohort,
C1q-fixation to CSP negatively correlated with IgG to
MSP2 and AMA1 (rho = − 0.453, p = 0.001; rho = − 0.443,
p = 0.002, respectively). Collectively, these data suggest
that increased malaria exposure negatively impacts the in-
duction of functional immunity by RTS,S immunization.
Functional antibodies are poorly sustained after RTS,S
vaccination
To assess long-term RTS,S-induced immunity, we exam-
ined a random selection of children from the Manhiça
cohort (n = 30) with samples available at months 3, 8.5,
21, 33, 45, and 63 (5-year follow-up). Maximal
C1q-fixation responses were observed at M3, which then
significantly declined by M8.5 (OD median, 2.363 and
0.174, respectively; p < 0.001) (Fig. 6a and Add-
itional file 1: Figure S6). Sera were re-tested at a higher
concentration (1/110 dilution), and a similar result was
obtained. Interestingly, a small number of individuals
did maintain complement-fixing activity for a longer
period (Additional file 1: Figure S6). Antibody concen-
tration is known to effect complement activity, and
therefore, the decline in C1q-fixation responses may
have been due to antibody levels being below the re-
quired functional threshold (Additional file 1: Figure S7).
IgG and IgM responses to CSP also waned over time,
although this did not appear as marked as the loss of
C1q-fixing antibodies (Fig. 6b). Given that IgG subclass
strongly influences antibody function, we examined the
decay of each IgG subclass response with respect to the






































C1q   IgG      IgM
C1q-high                  C1q-low
Fig. 4 High variability among RTS,S vaccine-induced IgG targeting the central repeat and C-terminal regions of CSP. Children in RTS,S vaccine
group from Manhiça and Ilha Josina cohorts (N = 99, 3 M) were tested for IgG to NANP and CT and C1q-fixation to CSP, and the values were used
for the following analysis. a Heat map of children arranged in descending (top to bottom) order of C1q-fixation (left), corresponding IgG to NANP
and CT (middle), and for comparison IgM to NANP and CT (right). b Variability between epitope specificity was quantified by calculating the ratio
of NANP-to-CT IgG. Children with low variability were considered to have equal reactivity to NANP and CT (ratio between 0.75 and 1.25 shown in
white), and children exceeding this range were considered to have a NANP- or CT-skewed response (ratio > 1.25 shown in purple and ratio <
0.75 shown in blue, respectively). Children were arranged in descending order of C1q-fixation (left to right), whereby those in the top quantile are
in black bars (C1q-high, OD range 2.03 to 4.00) and those in the bottom quantile are in gray bars (C1q-low, OD range 0.02 to 1.97). c Pie charts
representing the percentage of children with the following epitope-specific IgG profiles from C1q-high and C1q-low groups: NANP-skewed,
equal, and CT-skewed
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and IgG3 responses both declined substantially over
time, consistent with the decline in complement-fixing
antibodies.
Modeling the decay of complement-fixing antibodies
Determining the decay rate of specific antibody types is im-
portant for understanding the duration of vaccine-induced
immunity and informs how this may be improved in the fu-
ture. Therefore, we developed methods to estimate the
decay rates of complement-fixing antibodies, IgG subclasses,
and IgM, using latent growth curve modeling (Table 1).
Antibody decay followed a largely exponential decay, and a
log of the data was used to normalize the data. Descriptively,
the rate of decline of IgG1, IgG2, and IgG3 was similar,
whereas IgM decay was slower. IgG4 was estimated to have
a slow decay rate; however, the levels of IgG4 were very low
overall. The rate of decay of complement-fixing antibodies
was higher than that seen for total IgG. The half-life of
complement-fixing antibodies was relatively short (5.2 [3.8–
6.5] months) compared to that of IgG1 (8.4 [6.0–10.8]
months), IgG2 (10.8 [5.70–15.9] months), and IgG3 (8.6
[6.2–10.9] months) subclass responses.
To better understand the factors contributing to the
decline in complement-fixing antibodies over time, we



























































Fig. 5 Relationship between age and immunity. Children in RTS,S
vaccine group from Manhiça (black box plots) and Ilha Josina
cohorts (gray box plots) were categorized into younger (12 to 24
months; Manhiça n = 11 and Ilha Josina n = 23, respectively) and
older (24 to 60 months; Manhiça n = 39 and Ilha Josina n = 26,
respectively) age groups. Sera collected after vaccination (month 3,
M3) were tested for C1q-fixation to CSP and NANP (a) and IgG-
reactivity to blood-stage antigens MSP2 and AMA1 (b). Samples
were tested in duplicate, and the mean value was used to generate
box plots for samples stratified by age group. Top, center, and
bottom horizontal lines represent the 75th percentile, median, and
25th percentile, respectively; upper and lower whiskers represent the
highest and lowest values within 1.5× IQR, respectively; and values
that exceed this range are presented as dots. Malaria-naïve negative
controls from Melbourne donors were used to calculate the
seropositivity cutoff values (dashed lines), and the percentages of
individuals above this threshold are shown. Reactivity between




























































Fig. 6 RTS,S vaccine-induced immunity declines over time. A
random selection of children vaccinated with RTS,S (Manhiça cohort,
n = 30) was tested for C1q-fixation (a), IgG/IgM (b), and IgG
subclasses (c) to CSP at months 3, 8.5, 21, 33, 45, and 6. Note that
due to low reactivity, C1q-fixation was re-tested at a higher dilution
of 1/110, in addition to 1/250, to confirm results. Samples were
tested in duplicate, and the median and 95% CI of the median from
each time point group are shown by the symbol and shaded
area, respectively
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developed a model to determine which antibodies most
strongly correlated with declining complement-fixing ac-
tivity using the repeated measures data. We undertook
nested multivariable mixed modeling to estimate the
unique variance of complement-fixing antibodies by
each antibody response type (Table 2). The analysis indi-
cated that longitudinal complement-fixation responses
were most strongly independently associated with IgG1
(f2 = 0.38, Wald χ2(2) = 55.3; p < .001) and there was also
a significant correlation with IgG3 (f2 = 0.18, Wald χ2(2)
= 29.5; p < .001). There was no significant association
with IgG2, IgG4, or IgM.
Discussion
Knowledge of the induction and maintenance of func-
tional immune responses by RTS,S is valuable for stra-
tegically improving vaccine design and delivery to
generate a highly efficacious and longer-lasting malaria
vaccine. Here, we investigated RTS,S-induced antibody
responses in children and present new evidence of a
functional mechanism that may contribute to vaccine-
induced immunity. We show that RTS,S-induced
anti-CSP antibodies were predominantly IgG1, and there
was also a substantial induction of IgG3, IgG2, and IgM.
Antibodies among vaccinated children could strongly fix
complement on the whole, but functional responses did
vary among individuals. Our data suggest that antibodies
targeting both the central repeat and C-terminal regions
of CSP are important for complement fixation. Further-
more, functional antibodies were poorly induced in older
children with greater malaria exposure, and functional
antibodies were poorly maintained after vaccination.
This decline in complement-fixing antibodies was largely
due to a decline in IgG1 and to a lesser extent IgG3.
These findings highlight the diversity of RTS,S-induced
immune responses in malaria-exposed populations,
demonstrate a new functional mechanism of vaccine-
induced antibodies, and shed some light on the mainten-
ance and decay of vaccine immunity. Our findings
suggest that generating higher levels of complement-
fixing antibodies among a greater proportion of children,
and inducing responses that are durable over time, may
contribute to greater vaccine efficacy and durability.
IgG1 and IgG3 subclasses have the highest comple-
ment-fixing activity, whereas IgG2 and IgG4 have little
or no activity [25]. RTS,S/AS02A strongly induced
anti-CSP IgG1 followed by IgG3 and IgG2 in children
aged 1–4 years. Similar findings showing a predominant
IgG1 and IgG3 response were recently reported for a
subset (n = 195) of subjects from the phase III RTS,S/
AS01B vaccine trial of infants and young children (6–12
weeks and 5–17months). A higher ratio of cytophilic
antibodies (IgG1 and IgG3) to non-cytophilic antibodies
(IgG2 and IgG4) was associated with vaccine-induced
protection [8]. Therefore, we propose that one way in
which RTS,S-induced cytophilic antibodies may confer
Table 1 Associations between complement fixation, antibody
responses, and time using latent growth curve modeling (n =
30)
Outcomea bb (s.e.) 95% CI p valuec
log C1q − 0.42 (0.03) − 0.49, − 0.36 < 0.001
log IgG1 −0.33 (0.02) − 0.37, − 0.28 < 0.001
log IgG2 − 0.30 (0.02) − 0.33, − 0.26 < 0.001
log IgG3 − 0.32 (0.02) − 0.36, − 0.28 < 0.001
log IgG4 − 0.03 (0.004) − 0.04, − 0.02 < 0.001
log IgM − 0.12 (0.02) − 0.16, − 0.09 < 0.001
aEffects for each factor represent separate linear mixed modeling (LMM)
analyses where the natural log of C1q-fixation and each antibody response is
regressed on the natural log of time (per month). These LMMs applied a
random intercept for study participant, random slope for log time with an
unstructured covariance parameter specified for the correlation between the
random effects
bRegression coefficient (b) and standard error (s.e.) represent the percent
change in C1q-fixation or antibody response for a percent increase in time
cProbability values based on Wald statistics
Table 2 Associations between antibody responses and
complement fixation activity over time using linear mixed
modeling (n = 30)
Factora bb (s.e.) 95% CI p valuec f2d
IgG1 0.38
Linear term 1.10 (0.16) 0.78, 1.41 < 0.001
Interaction term − 0.28 (0.05) − 0.38, − 0.18 < 0.001
IgG2 0.02
Linear term 0.11 (0.13) − 0.14, 0.37 0.388
Interaction term − 0.01 (0.05) − 0.10, 0.08 0.805
IgG3 0.18
Linear term 0.54 (0.15) 0.24, 0.83 < 0.001
Interaction term − 0.07 (0.05) − 0.18, 0.03 0.177
IgG4 0.02
Linear term 0.21 (0.86) − 1.47, 1.90 0.802
Interaction term 0.07 (0.31) − 0.53, 0.68 0.808
IgM 0.03
Linear term − 0.21 (0.18) − 0.57, 0.38 0.233
Interaction term − 0.02 (0.07) − 0.11, 0.15 0.792
aLinear mixed modeling (LMM) analyses where the natural log of C1q-fixation
was regressed on the natural log of antibody responses (linear term)
conditioning on other antibody response factors to provide an independent
association. This LMM model included a term for the natural log of time (not
shown) and relaxed the constraint of a consistent association between C1q-
fixation and antibody responses across time (interaction term). The LMMs
applied a random intercept for study participant and random slope for time
bRegression coefficient (b) and standard error (s.e.) represent the percent
change in participant C1q-fixation level for a percent increase in
antibody responses
cProbability values based on Wald statistics
dCohen’s f2 represents the ratio of the unique variance explained by a specific
antibody response factor to the variance explained by an intercept-only
model. Higher values indicate a stronger effect
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protection is by interacting with human complement, a
mechanism that has been previously associated with
protection in studies of naturally acquired immunity to
sporozoites in children [17]. The AS01B and AS02A
adjuvants both contain TLR4 agonist MPL and the sap-
onin QS-21, but AS01B is a liposome-based adjuvant
whereas AS02A is an oil-in-water emulsion [26]; RTS,S
administered with either adjuvant appears to induce
similar IgG subclass profiles in malaria-exposed children.
In the phase III study, post-vaccination levels of IgG2
and IgG4, but not IgG1 and IgG3, to CSP were signifi-
cantly higher in the high malaria transmission site com-
pared to the low malaria transmission site [8]. It is
noteworthy that studies in malaria-naïve adults found
RTS,S to predominately induce IgG1 and IgG2 only
[27–29], which demonstrates that immunogenicity can
substantially differ in malaria-exposed populations com-
pared to malaria-naïve individuals in non-endemic coun-
tries. Such differences are poorly understood but require
a greater understanding, particularly because IgG3 is a
potent mediator of complement fixation and activation.
The use of adjuvants or vaccine regimens that increase
IgG3 and reduce IgG2 induction is likely to lead to re-
sponses with greater complement-fixing activity and po-
tentially greater efficacy.
Complement activity can also be mediated by IgM
antibodies. Interestingly, anti-CSP IgM seropositivity
was moderate at baseline, although functional C1q-
fixation responses were only apparent after RTS,S vac-
cination when IgM (and IgG) had significantly increased.
Modeling the decay of antibodies over time suggests
IgM is not a major mediator of complement-fixing activ-
ity, and this was instead largely mediated by IgG1 and
IgG3. The role of IgM in immunological memory is not
well established, but a recent study demonstrated that
IgM memory B cells were long-lived and involved in sec-
ondary responses using a murine model of malaria [30],
and IgM responses remain present even in those with
extensive malaria exposure [31].
Complement activity is also influenced by epitope-
specificity [32–34]. We found that RTS,S-induced anti-
bodies were most potent at fixing complement to the
central repeat region of CSP, but antibodies to the
C-terminal region could also fix complement. Interest-
ingly, children with higher complement-fixing antibodies
tended to have equal levels of IgG to both CSP regions,
whereas those with low functional antibodies were more
frequently epitope-skewed. Therefore, antibodies to both
regions may better promote immune complex formation
that leads to complement fixation and activation.
Overall, there were highly diverse IgG epitope profiles
among children. In field evaluations of RTS,S, only IgG
to the central repeat region have been typically mea-
sured and reported. This is likely because RTS,S-induced
antibodies to the central repeat region, but not the
C-terminal region, show some association with protec-
tion in studies of healthy malaria-naïve adults [10, 29,
35–37]. However, the relationship between protection
and repeat-specific antibodies has been inconsistently re-
ported in field evaluations of malaria-exposed children
and infants [18, 38, 39]. A recent study found that anti-
bodies to both regions of CSP, that were of a specific
IgG subclass, were associated with protection in the
phase III clinical trial of RTS,S/AS01B [8]. Additionally,
the central repeat region is considered immunodomi-
nant as it is a major target of antibodies induced by
whole irradiated attenuated sporozoite vaccines and nat-
ural malaria exposure [40, 41], and repeat-specific anti-
bodies can block sporozoite infectivity in vitro [42].
However, antibodies to non-repeat regions are also nat-
urally acquired and have demonstrated inhibitory activity
in vitro [43–47]. Taken together, our data support the
importance of antibodies to the central repeat region of
CSP, but also encourage further investigation of antibody
responses to the C-terminal region, particularly because
repeat-specific antibodies alone are a poor correlate of
protection.
RTS,S-induced antibodies strongly fixed complement
to CSP, but overall functional activity among vaccinated
children markedly declined by M8.5. Although total IgG
remained moderate at this time, reactivity may have
dropped below the threshold required to detect func-
tional activity using our methods, particularly because
antibody density is known to influence complement ac-
tivity, as multiple C1q monomers (six in total) bind
neighboring IgG molecules to initiate the classical com-
plement pathway [32]. Our statistical modeling indicated
that the rapid decay of complement-fixing antibodies
was mostly explained by the decline in IgG1 and to a
lesser extent IgG3, likely because both subclasses can
potently fix complement and because IgG1 was the pre-
dominant subclass induced by vaccination. Perhaps, if
RTS,S induced greater levels of IgG3 that were above
the antibody threshold needed for functional activity and
were more durable, complement-fixing antibody re-
sponses may have better maintained after vaccination.
Including measures over time enabled a better under-
standing of the relationships between specific antibody
types and complement fixation than analysis performed
at a single cross-sectional time point. While the decay
post-immunization of IgG to the central repeat region
has been reported [48], there are no data on the decay
of functional antibodies, IgG subclasses, or IgM. Add-
itionally, no malaria vaccine studies have reported the
relationship between IgG or IgM and functional anti-
bodies over time. Therefore, our new statistical methods
developed for this study may be valuable for understand-
ing these responses in other RTS,S trials and studies of
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other malaria vaccines. It is possible that functional anti-
bodies, IgG subclasses, and IgM have different responses
and kinetics after booster immunizations. The decay of
complement-fixing antibodies was broadly consistent
with the decline in RTS,S vaccine efficacy for this trial.
Statistical analyses estimated that initial efficacy against
clinical malaria was ~ 30% in the first 4–5 months but
quickly waned to limited efficacy 18–30 months after
vaccination. In our studies, some children retained sig-
nificant complement-fixing antibodies at M8.5, which
may contribute to some continuing vaccine efficacy. Our
findings suggest these questions warrant investigation in
the phase III trials to better understand the efficacy and
durability of RTS,S.
The present study was conducted in a malaria-
endemic setting, and therefore, children will have vary-
ing degrees of malaria exposure and naturally acquired
immunity. Older children in the higher malaria trans-
mission site, Ilha Josina, had significantly lower levels of
complement-fixing antibodies. This was also observed
for total IgG to CSP, but the effect was not as pro-
nounced. Older children also had higher levels of anti-
bodies to blood-stage antigens, and this inversely
correlated with vaccine-induced anti-CSP antibodies,
which has been previously reported [49, 50]. Interest-
ingly, these trends were only clear in the Ilha Josina
study site, where transmission intensity was approxi-
mately tenfold higher than the Manhiça site. These find-
ings suggest that age and higher levels of malaria
exposure negatively impact on the induction of func-
tional antibodies by the RTS,S vaccine. This is a signifi-
cant finding that has implications for generating
immunogenic and efficacious malaria vaccines in high
transmission zones. The biological basis for this effect is
not known but could be due to T or B cell exhaustion
from repeated exposure [51], or naturally acquired im-
munity could be interfering with the induction of vac-
cine immunity. Understanding this issue is a priority for
further research.
Conclusions
We have provided a detailed characterization of RTS,S-
induced antibody responses in malaria-exposed children
and identified a new functional antibody activity induced
by RTS,S. This is an important finding as recent studies
demonstrated that complement fixation by antibodies
could inhibit sporozoite traversal and lead to sporozoite
cell death [16, 17], suggesting that RTS,S-induced
immunity may function, in part through complement
fixation. Our data demonstrates highly diverse patterns
of epitope specificity among children and raises the po-
tential role of the C-terminal region of CSP in functional
immunity, in addition to antibodies targeting the NANP
region. This finding calls for further examination of how
antibodies to the C-terminal region may co-operatively
promote antibody function, such as complement activa-
tion. Complement-fixing antibodies were generally rela-
tively short-lived and were less effectively induced in
older children with higher malaria exposure, which
could be important for vaccine implementation in loca-
tions with high malaria transmission intensity and
should be further evaluated. Furthermore, we developed
statistical methods to investigate antibody decay and
relationships over time post-vaccination; these ap-
proaches could be highly valuable in future vaccine trial
evaluation, especially as a tool to investigate the determi-
nants of vaccine longevity and inform strategies to
improve this. Our findings support future investigation
of the large phase III trials to determine whether
complement fixation is a valuable correlate of protective
immunity and advance the development of more effica-
cious and long-lasting vaccines.
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